New EU medicines 2026: what logistics and warehousing must deliver before launch

CHMP opinion, EU authorisation and market launch are separate milestones

A positive CHMP opinion is the scientific basis for a later European Commission decision, not a market-ready launch. The approved product information ultimately defines storage, shelf life and handling requirements.

Logistics teams should nevertheless model dosage form, expected batch size, product value, target markets and possible temperature bands early because these inputs shape the warehouse, technology, data model and supplier qualification.

18 new medicines from the June and July 2026 CHMP meetings

The direct index leads to each product and active substance. It reflects CHMP-opinion stage; the subsequently approved product information governs operational decisions.

Warehouse readiness: zoning, quarantine and release before receipt

Before arrival, each product needs a qualified zone and clear status locations for quarantine, released, blocked and returned stock. Cold-chain or high-value products add alarm management, access control, emergency power, backup capacity and a controlled transfer plan.

• Capacity and zoning by product and season
• Temperature mapping, monitoring and alarm escalation
• FEFO, batch and expiry management
• Physical and system status blocks
• Qualified contingency storage

WMS, QMS and serialisation must share one product identity

Item number, GTIN, batch, expiry, serialisation, market release and temperature status cannot diverge across data silos. Product setup should be a controlled master-data process with dual review, test cases and documented approval.

Clear identity is particularly important for generics and biosimilars; a similar active-substance name is never a substitute for product-level verification.

Launch inventory: little history, high value and uncertain demand

Orphan medicines, implants, vaccines and specialist biologics often combine small volumes with high shortage risk. Safety stock, ordering cadence and insurance require scenarios for delayed release, demand peaks, partial batches, market shifts and recalls.

A launch control tower should connect forecast, released batch, quality status, days of cover, open orders and transport capacity.

Transport, packaging and last mile as a qualified lane

The approved product information determines the final temperature regime. Setup must still assess summer and winter profiles, maximum transit, hubs, border risks, logger strategy, handovers and consignee opening hours. Qualified packaging does not compensate for uncontrolled dwell time.

Appointment-linked products also require confirmed receipt, proof of delivery and escalation before a stability limit is threatened.

Returns, deviations, CAPA and recall readiness

Returns cannot automatically re-enter saleable stock. Time outside control, transport data, tamper evidence, serialisation and chain of custody require documented review. The same applies to temperature alarms and late handovers.

Recall readiness means connecting batch, consignee, warehouse status and transport movement quickly; exercises expose gaps before a real event.

How Inter-Pharma makes logistics and warehousing launch-ready

Inter-Pharma helps manufacturers, distributors and healthcare businesses translate new product profiles into controlled European supply chains. Support covers warehouse and capacity design, GDP risk assessment, zoning and temperature concepts, WMS/QMS requirements, SOPs, supplier qualification, lane design, packaging strategy, deviations, recalls and operational launch control.

The greatest value lies at the interfaces: quality, warehouse, IT, transport, procurement and market teams work from one process and data model.